Coca-Cola Europacific Partners: Volume Returns, Pricing Holds, and the Inflation Hedge That Grows Its Own Dividend

There is a difference between a company that raises prices and a company that grows volumes while raising prices. One is a last-ditch effort to protect margins. The other is pricing power worth paying for.

Coca-Cola Europacific Partners reported its first-half 2026 results today, and the second description is the one that fits. Revenue reached €10,724m, up 6.1% on an FX-neutral basis. Earnings per share growth of 10.6% to €2.17. Solid operating profit growth of 8.1%. But the number I circled first wasn't top-line or bottom-line - it was volume. The company returned to solid volume growth across both Europe and Asia-Pacific after a year of flat-to-negative unit movement.

That matters because volume growth in a consumer staples bottler is the ultimate stress test for pricing power. If a company can raise prices and still sell more product, it does not need to hope that inflation continues. It can grow its way through any inflation regime.

Here is what the first-half results tell us about CCEP's place in a portfolio built for persistent inflation and durable income growth.

1. The volume story changed, and that changes the thesis

For most of 2025, CCEP's volume growth was essentially flat. Adjusted comparable volumes came in at just +0.2% for the full year. Investors could make a valid case that the company was growing revenue and profit almost entirely through price. That works for a while, but not forever - eventually the consumer pushes back, and revenue per unit case stops climbing.

The first half of 2026 is different. Q1 saw comparable volume growth of 1.6%, with Europe at +1.4% and Asia-Pacific at +1.9%. Mid single-digit volume growth driven by Coca- Cola Zero Sugar. Revenue per unit case still rose, but the company is no longer relying on price alone.

This is the pattern I look for when evaluating whether a consumer staples company has real pricing power or just temporary tailwinds. Price without volume is a loan from the consumer that eventually comes due. Price with volume is the real deal.

2. Pricing power is not a binary - it's a margin engine

CCEP targets a cost-of-sales-per-unit-case increase of around 1.5% for full-year 2026, while revenue per unit case grew 0.8% in Q1 alone and has been climbing steadily throughout the year. That spread - revenue growth outpacing cost growth - is the margin expansion that funds dividend growth and free cash flow.

In an inflation regime that runs hotter than the traditional 2% target, this spread is everything. A company that cannot raise prices faster than its input costs gets squeezed on both sides. CCEP has demonstrated, year after year, that it can do the former. Coca-Cola Zero Sugar, energy drinks, and premiumisation in water and RTD coffee are not just category growth stories. They are structural pricing levers.

The company's full-year 2026 guidance for roughly 7% operating profit growth against 3–4% revenue growth is the quantifiable expression of that leverage. Operating profit is growing nearly double the rate of revenue because every euro of top-line growth carries more margin than the last.

3. The dividend grows at 12% a year, and that's the real story

CCEP's current dividend yield sits at 2.24%. That number alone will not set your heart racing if you're chasing income. The dividend has grown at an average of 12% per year over the past decade. The 2026 annual dividend is €2.09 per share, up from €2.04 in 2025, €1.97 in 2024, and €1.61 back in 2022.

Let me put the compounding in perspective. A 2.2% yield growing at 12% per year reaches 5% yield on cost in roughly eight years. In 15 years, it's roughly 10%. In 20 years, closer to 15%. This is not a static income play. It is a compounding income machine, and the equity yield curve - the relationship between starting yield and dividend growth - tells us that moderate-yield, high-growth dividend stocks in the 2–4% range are where the best long-term returns are generated.

The payout ratio is targeted at approximately 50% of comparable earnings. At the midpoint of CCEP's 2026 EPS guidance of €4.46, a 50% payout ratio means the dividend is funded by roughly half of earnings. The other half covers reinvestment, buybacks, and builds a cushion for slower quarters. That is a sustainable payout structure.

4. Free cash flow proves the dividend is real

Dividend safety is not about whether a company can afford its payout today. It's about whether free cash flow consistently clears the dividend bar and leaves something behind for reinvestment and return of capital.

In full-year 2025, CCEP generated €1.836 billion in comparable free cash flow. The company's 2026 guidance targets at least €1.7 billion. With a €2.09 per-share dividend and roughly 151 million shares outstanding, the annual dividend payout is around €315 million. Free cash flow covers that at roughly five to six times. Even after the €1 billion share buyback announced for 2026, there is substantial cash remaining.

That is what a healthy payout looks like. The dividend is not the entire free cash flow budget. It's a fraction of it, and the fraction is getting smaller as earnings and cash flow grow faster than the dividend.

5. The leading indicators are on CCEP's side

The ISM Manufacturing PMI jumped to 55.6 in July 2026 - the strongest reading since May 2022. New orders came in at 56.7. Prices were increasing. This is not the kind of economic backdrop where consumer staples struggle with volume. It's the kind of backdrop where beverage consumption holds up, away-from-home channels recover, and companies with pricing power can execute.

CCEP's Q1 volume growth story was partly supported by an earlier Easter and six extra consumption days. Calendar effects fade, and I'm not counting them as structural. But the underlying trajectory - Coca-Cola Zero Sugar gaining share, energy drinks growing double-digit, away-from-home channels recovering in Great Britain and across Europe - is secular, not cyclical. These are consumption trends that do not reverse because the PMI moves from 55 to 52.

6. Valuation at 21x earnings is not a bargain, but it's not unjustified

CCEP trades at roughly 21 times trailing earnings, with an EV/EBITDA multiple of 14x. For comparison, Mondelez - a consumer staples peer with global distribution but no bottling franchise - trades at 22.4x earnings and 16.6x EV/EBITDA. CCEP is not expensive relative to its closest category peers.

I don't think this stock is cheap. It's not one of those out-of-favor dividend growers sitting at 15x earnings with a distressed yield. The market is already paying for the quality of the franchise, the consistency of cash flow, and the dividend growth trajectory. But at 21x, you are not overpaying for a company that grows earnings in the mid-to-high single digits, generates €1.7+ billion in annual free cash flow, and compounds its dividend at double-digit rates.

The risk/reward here is not about buying a deeply undervalued stock. It's about owning a high-quality compounding business at a fair price and letting time and dividend reinvestment do the work.

What could go wrong

Three risks deserve honest acknowledgment. First, Europe's consumer environment remains fragile in pockets - wage growth hasn't caught up to inflation in several of CCEP's core markets, and a recession could pressure volumes again. Second, the €1 billion buyback program is a double-edged sword: it boosts earnings per share and supports the stock price, but it also uses capital that could fund dividend growth or reduce leverage if conditions deteriorate. Third, input cost inflation in aluminum, plastic resins, and energy could compress margins if CCEP cannot fully pass them through. I've been impressed by the company's track record, but no bottler is immune to a cost shock that moves faster than their pricing cycle.

The bottom line

Coca-Cola Europacific Partners is not a stock I would treat as a yield shortcut. It belongs in the income-growth sleeve of a portfolio because the combination of pricing power, balance-sheet strength, and dividend growth trajectory supports compounding through a full cycle. The H1 2026 results reinforced that case: volume returned, pricing held, operating profit grew nearly twice as fast as revenue, and free cash flow coverage of the dividend remains comfortable.

I believe the structural case for CCEP is stronger in an inflation regime that runs above traditional targets, because the company has proven it can raise prices without losing customers - the single most important test a dividend grower can pass. The 2.24% yield is the entry point. The 12% dividend growth rate is the engine. And the compounding math does the rest.

This may not fit every investor's portfolio. If you need 5% of current yield tomorrow, there are higher-paying alternatives. But if you're building income that compounds faster than inflation and you're willing to accept a fair price for quality, CCEP earns a place in the conversation.